Immatics is looking forward to sharing progress toward its mission of developing and delivering novel PRAME-targeted immunotherapies for patients with cancer.
Published
Signal category
Presence & Recognition
Quote
“As the summer winds down, we’re looking forward to getting back on the road and sharing the progress we’re making toward our mission: developing and delivering novel PRAME-targeted immunotherapies for patients with cancer.”
— Immatics team
Company
Immatics
The Global Leader in Precision Targeting of PRAME
- Industry
- Biotechnology Research
- Location
- Tuebingen, DE
- Company size
- 652 employees
Immatics is committed to making a meaningful impact on the lives of patients with cancer. We are the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers. Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities, spanning TCR T-cell therapies and TCR bispecifics. Read more about Immatics on our homepage: https://immatics.com/ Find us also on: Instagram: https://www.instagram.com/immatics/ YouTube: https://www.youtube.com/channel/UCv7uTpsGXvSNzwSX_xOtYSA Legal notice: https://immatics.com/imprint/
Founded 2000